The Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to exhibit a CAGR of 14.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Antibody-drug conjugates (ADCs) are bioconjugate compounds used for targeted drug delivery. They consist of monoclonal antibodies attached to a small-molecule drug or cytotoxic agent. The monoclonal antibody helps target the cancer cells and the cytotoxic agent then kills those cells. ADCs help deliver highly potent anti-cancer drugs directly to the tumor while limiting side effects in non-cancerous cells.
Market Dynamics:
The growing antibody drug conjugates market is driven primarily by its promising pipeline and strong R&D investments from major players. Several late-stage pipelines are expected to be commercialized during the forecast period, propelling market growth. For instance, AstraZeneca's Enhertu was approved in 2019 for HER2-positive breast cancer and non-small cell lung cancer indications. Furthermore, rising incidence of cancer worldwide has increased demand for targeted therapies like ADCs. Moreover, approvals of novel ADCs to treat blood cancers and solid tumors are also augmenting the market growth. However, high costs associated with developing ADCs and complex manufacturing processes pose challenges to market players.
SWOT Analysis
Strength: Antibody-drug conjugates allow targeted drug delivery to cancer cells. By attaching cytotoxic drugs to monoclonal antibodies, ADCs minimize damage to healthy cells. ADCs have high specificity and selectivity for tumor cells. Longer patent life of novel ADC over conventional chemotherapy drugs.
Weakness: High research and development costs associated with developing ADCs. Complex manufacturing processes require specialized infrastructure and expertise. Issues related to linker stability and drug-antibody ratio.
Opportunity: Large patient pool suffering from cancers drives demand for therapies with improved safety profiles over conventional chemotherapy. Increasing healthcare expenditure in developing countries to boost market growth. Growing pipeline of ADC candidates in clinical trials indicates potential for market expansion.
Threats: Stringent regulatory approvals require extensive clinical data, delaying market entry. Biosimilar competition once ADC patents expire poses pricing challenges. Adverse effects seen with some approved ADCs limit their adoption.
Key Takeaways
The Global Antibody Drug Conjugates Market is expected to witness high growth, exhibiting CAGR of 14.2% over the forecast period, due to increasing demand for targeted cancer therapies with fewer side effects.
Regional analysis
The US dominates the global ADC market, accounting for majority market share, owing to presence of advanced healthcare infrastructure and favorable reimbursement policies. Asia Pacific is the fastest growing regional market due to rising healthcare expenditure, improving diagnostic capabilities and growing patient pool.
Key players
Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.
